Surgical & Medical Instruments & Apparatus · PETACH TIKVA, L3, Israel
$5.15
-4.45% (-$0.24)2026-07-20
Smart-Money SignalNeutral · 51/100— Insiders are net buyers over 90 days ($1.5M, 5 buys vs 0 sales)
Price Performance
Historical data including institutional events
Company Profile
D
Dikla Czaczkes Akselbrad
CEO & Executive Director
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- Founded
- 2008
- Employees
- 75
- Headquarters
- PETACH TIKVA, L3, Israel
- Website
- www.polypid.com
Peer ComparisonRevenue ($B)
▾Loading company sections...